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Effect of Probiotic Lactobacillus (Lacidofil® Cap) for the 
Prevention of Antibiotic-associated Diarrhea: A Prospective, 
Randomized, Double-blind, Multicenter Study
Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic use. There 
is growing interest in probiotics for the treatment of AAD and Clostridium difficile 
infection because of the wide availability of probiotics. The aim of this multicenter, 
randomized, placebo-controlled, double-blind trial was to assess the efficacy of 
probiotic Lactobacillus (Lacidofil® cap) for the prevention of AAD in adults. From 
September 2008 to November 2009, a total of 214 patients with respiratory tract 
infection who had begun receiving antibiotics were randomized to receive Lactobacillus 
(Lacidofil® cap) or placebo for 14 days. Patients recorded bowel frequency and stool 
consistency daily for 14 days. The primary outcome was the proportion of patients 
who developed AAD within 14 days of enrollment. AAD developed in 4 (3.9%) of 103 
patients in the Lactobacillus group and in 8 (7.2%) of 111 patients in the placebo 
group (P=0.44). However, the Lactobacillus group showed lower change in bowel 
frequency and consistency (50/103, 48.5%) than the placebo group (35/111, 31.5%) 
(P=0.01). Although the Lacidofil® cap does not reduce the rate of occurrence of AAD 
in adult patients with respiratory tract infection who have taken antibiotics, the 
Lactobacillus group maintains their bowel habits to a greater extent than the placebo 
group. 
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INTRODUCTION
Antibiotic-associated diarrhea (AAD) is emerging as a common 
complication of antibiotic use. The frequency of AAD can be 
high (26-60%) during hospital outbreaks or intermediate (13-
29%) during endemic periods and is relatively low in outpatient 
settings (usually less than 0.1%) (1, 2). Risk factors for AAD in-
clude the use of broad-spectrum antibiotics, various host fac-
tors (old age, poor general condition), a longer hospitalization 
period and exposure to nosocomial pathogens (1-3). AAD can 
occur 2 to 8 weeks after exposure to antibiotics as a result of dis-
ruption of intestinal microflora. One of the main roles of normal 
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gut microflora is to protect against colonization by intestinal 
pathogens (4). Once this protective barrier is broken, patients 
are more susceptible to infection with opportunistic pathogens. 
Probiotics have been proposed to treat AAD and Clostridium 
difficile disease. Probiotics mainly assist in re-establishing the 
disrupted intestinal microflora, enhancing immune responses 
and clearing pathogens and their toxins from the host (5-7).  
 There is growing interest in probiotics for the treatment of 
AAD and C. difficile disease because of the wide availability of 
probiotics as dietary supplements and concern over recent out-
breaks of severe C. difficile disease in Canada and the United 
Kingdom (8, 9). Research on probiotics has been reported for 
the past 28 yr (1977-2005), but the studies have been variable in 
trial design, type of probiotic and dosage and duration of treat-
ment, and thus have often yielded contradictory results (10). 
Twenty–five randomized, controlled trials (RCTs) provided ad-
equate data regarding the efficacy of probiotics for the preven-
tion of AAD (10). Of the 25 RCTs, only 6 utilized Lactobacillus 
rhamnosus (11-16).
 There were a few RCTs that proved the efficacy of Lactobacil-
lus in preventing AAD, and debate arose regarding the study 
populations. A study on the use of L. rhamnosus (2×1010 colon-
forming units per day) for preventing AAD in 302 adults receiv-
ing antibiotics at the Mayo Clinic showed no efficacy of L. rham-
nosus in decreasing the overall incidence of AAD because quite 
a few patients had stool cultures, additional tests for diarrhea, 
or a positive diagnosis of C. difficile (15). However, 89 patients 
in a recent RCT on the daily administration of a Lactobacillus-
fermented milk product showed that it was safe and effective in 
the prevention of AAD (17). A recent RCT involving 135 patients 
demonstrated that a probiotic Lactobacillus preparation pre-
vented AAD and C. difficile-associated diarrhea (18).
 Therefore, we conducted a multicenter, randomized, place-
bo-controlled, double-blind trial to assess the efficacy of probi-
otic Lactobacillus (Lacidofil® cap) for the prevention of AAD in 
Korean adults.
MATERIALS AND METHODS
Participants
Adult patients receiving antibiotic therapy for respiratory tract 
infection were screened at 10 tertiary hospitals. The inclusion 
criteria were adult inpatients aged >18 yr who received oral or 
injected antibiotics for respiratory tract infections within 48 hr 
of enrollment. The following patients were excluded from the 
study: 1) those who were diagnosed with C. difficile colitis with-
in the previous 3 months, 2) those who were given tube feeding 
or who underwent an ileostomy or colostomy, 3) those with bas-
al diarrheal disease (acute enteritis, inflammatory bowel dis-
ease, radiation enteritis, ischemic colitis and diarrhea caused 
by carcinoid), 4) those receiving other probiotics during the pre-
vious 15 days, 5) those treated with immunosuppressant drugs 
and those with immune deficiency, 6) those who underwent 
radiotherapy or chemotherapy treatment for cancer, 7) those 
treated with antidiarrheal, antispasmodic or motility agents for 
other diseases, 8) pregnant or lactating women, 9) those who 
underwent gastrointestinal surgery 3 months prior to the study, 
10) those with a history of hypersensitivity to cephalosporins, 
penicillin or clavulanic acid, 11) those with verified diabetic au-
tonomic neuropathy, 12) those who underwent organ transplan-
tations, and 13) those with underlying conditions or diseases 
who, in the opinion of the investigator, were unsuitable for in-
clusion.
 
Study design
Between September 2008 and November 2009, a total of 214 
patients with respiratory tract infection who had begun to re-
ceive antibiotics were randomly allocated to receive Lactobacil-
lus (Lacidofil® cap) or a placebo for 14 days. This study was con-
ducted at 10 investigational centers. Participants recorded their 
bowel frequency and stool consistency every day for 14 days. 
The primary outcome (AAD-1) was defined as loose or watery 
stools more than 3 times per day for at least 2 days within 14 days 
of enrollment. The secondary outcome (AAD-2) was defined as 
loose or watery stools more than 2 times per day for at least 2 
days within 14 days of enrollment. 
 The admitting medical team identified eligible patients who 
had an antibiotic prescription for the treatment of respiratory 
tract infection. After the investigators obtained informed con-
sent, they collected baseline data and prescribed the study drug 
on a randomized basis. The hospital pharmacy dispensed the 
drug. The treatment group received a probiotic preparation (Lac-
idofil® cap) containing L. rhamnosus R0011·L. acidophilus R0052 
bacterial culture (2×109 colony-forming units), maltodextrin, 
Mg stearate, and ascorbic acid. The control group received a pla-
cebo drug composed of maltodextrin, Mg stearate and ascorbic 
acid. Participants began using the Lacidofil® cap or placebo drug 
within 48 hr of initiation of antibiotic therapy. The Lacidofil® cap 
and placebo were administrated at a dose of 1 capsule twice a 
day for 14 days. The administration of other drugs for accompa-
nying diseases permitted subject to the investigator’s judgment. 
The use of antidiarrheal (e.g., loperamide, polypcarbophil), an-
tispasmodic (e.g., tiropramide, pinaverium, buscopan) or motil-
ity agents (e.g., domperidone, mosapride, itopride, levosulpride) 
that could affect the symptoms was prohibited. These drugs were 
withheld until the patient developed AAD, after which their use 
was allowed. 
 Investigators followed up participants for 14 days to check 
stool frequency, stool consistency and compliance. If partici-
pants had AAD, investigators collected further data on clinical 
symptoms and blood test results. As the safety of Lacidofil® cap 
has already been proven, its safety was not evaluated in this study.
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Sample size
We estimated that the minimum sample size was 220 for each 
group. The sample size was calculated on the basis of an 18% 
difference in the proportion of AAD compared with the control 
group with an expected compliance rate of 80%, a statistical pow-
er (two sided) of 90%, a significance level of 5% and a dropout 
rate of 10%.
Randomization and double blinding
Among patients with respiratory tract infection, those who met 
the inclusion criteria were selected and allocated trial numbers. 
The subjects were allocated to the treatment (Lacidofil® cap treat-
ment) or control groups (placebo) according to their trial num-
bers. To maintain double-blinding, the envelope containing the 
random trial number allocation code was sealed by the investi-
gators, and the treatment allocations were not disclosed until the 
clinical trial was completed, except for cases for which access to 
the code was necessary. All investigators, participants, outcome 
assessors and data analysts were blinded throughout the study. 
Statistical analysis
SPSS for Windows software (V. 13.0, SPSS, Chicago, IL, USA) was 
used for statistical analysis. The chi-square test was used to de-
termine the difference in the incidence of AAD between the 2 
groups, and the Student’s t-test was used for analysis of contin-
uous variables. Multiple logistic regression analysis was used to 
identify the risk factors for AAD, and effect estimates are pre-
sented as the odds ratio (OR) and 95% confidence interval (CI). 
For all analyses, a P value of 0.05 or less (two sided) was consid-
ered significant.
Ethics statement 
The Institutional Review Board (IRB) of each hospital approved 
the study protocol (Ewha Womans University Mokdong Hospi-
tal, IRB No. 187-17). Written informed consent was obtained 
from each patient.
RESULTS
Participant flow and baseline characteristics of 
participants
Patient flow is summarized in Fig. 1. Over the 14-month study 
period, 286 patients were screened as potential candidates for 
this study by nurses. Of the 286 patients screened, 18 met 1 or 
more of the exclusion criteria, 28 did not meet all of the inclu-
sion criteria, and 26 refused to participate in the study. Of the 
214 patients who met the inclusion criteria and agreed to par-
ticipate in the study, 42 failed to complete the study. Finally, 172 
patients completed the study. Of the 42 patients who failed to 
complete the study, 5 had adverse events, 12 received contrain-
dicated drugs, 21 did not continue the treatment protocol, and 
4 were lost to follow-up. We performed intention-to-treat (ITT) 
analysis of data from 214 patients and per-protocol (PP) analy-
sis of data from 172 patients.
 Baseline characteristics are summarized in Table 1. The pla-
cebo (n=111) and the Lactobacillus groups (n=103) were simi-
lar in terms of their demographics and medical profiles at en-
rollment. There were no significant differences in total dose of 
antibiotics, baseline bowel movement, drug compliance, or pul-
monary infections between the 2 groups. Respiratory tract in-
fections, in descending order of frequency, were pneumonia, 
pulmonary tuberculosis, bronchitis, bronchiectasis, pleural ef-
fusion and upper respiratory tract infection. 
Excluded (n=72)
Ineligible (n=18)
Did not meet the inclusion  
   criteria (n=28)
Refused to participate (n=26)
Received placebo 
(n=111)
Completed study (n=89) Completed study (n=83)
Received Lactobacillus
(n=103)
Withdrawn (n=22)
Adverse events n=1
Administration of contra
-indicated drugs n=7
Not keen to continue n=13
Lost to follow-up n=1
Withdrawn (n=20)
Adverse events n=4
Administration of contra
-indicated drugs n=5
Not keen to continue n=8
Lost to follow-up n=3
Patients screened 
(N=286)
Randomized 
(n=214)
ITT 
(n=214)
PP 
(n=172)
Fig. 1. Patient flow diagram. 
Table 1. Baseline characteristics of study patients
Parameters
 Placebo  
 (n=111)
Lactobacillus 
(n=103)
P value*
Sex (male:female) 69:42 63:40 0.99
Age (yr)   60±16   61±15 0.88
BMI (kg/m2) 22.0±3.3 22.4±3.4 0.32
No medical illness 48 (43.2%) 43 (41.8%) 0.93
Total antibiotic use (days) 12.3±3.4 11.7±3.8 0.24
Baseline bowel movement  
   (per day)
  1.0±0.5   1.1±0.4 0.52
Loose stool or watery diarrhea  
   in normal condition
2 (1.8%) 1 (1.0%) 1.00
Drug compliance 88 (80.0%) 83 (80.6%) 1.00
Respiratory tract infection
   Pneumonia
   Pulmonary tuberculosis
   Bronchitis
   Bronchiectasis
   Pleural effusion
   Upper respiratory tract infection
79 (71.2%)
17 (15.3%)
6 (3.4%)
9 (8.1%)
1 (0.9%)
0 (0.0%)
80 (77.7%)
11 (10.7%)
12 (11.7%)
4 (3.9%)
3 (2.9%)
1 (1.0%)
0.35
0.42
0.16
0.31
0.35
0.48
*χ2 or Fisher exact test.
BMI, body mass index.
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 Antibiotic use for both groups is summarized in Table 2. The 
antibiotics used were, in descending order, cephalosporin, mac-
rolides, fluoroquniolones, antituberculosis drugs, clindamycin 
and penicillin. β-lactam antibiotics, including cephalosporins 
and penicillin, were commonly used in both the placebo and 
the Lactobacillus groups (75.7% vs 78.6%) (P=0.72). There were 
no significant differences in antibiotic use between the 2 groups. 
Analysis of outcome measures
In ITT analysis (n=214), AAD-1 developed in 4 (3.9%) of 103 pa-
tients in the Lactobacillus group and in 8 (7.2%) of 111 patients 
in the placebo group (P=0.44). AAD-2 developed in 9 (8.7%) of 
103 patients in the Lactobacillus group and in 16 (14.4%) of 111 
patients in the placebo group (P=0.28). There was no significant 
difference in AAD occurrence between the 2 groups. However, 
no changes in bowel frequency or consistency were reported by 
50 (48.5%) of 103 patients in the Lactobacillus group and by 35 
(31.5%) of 111 patients in the placebo group (P=0.01). Increased 
bowel frequency over a period of more than 3 days during the 
14-day period was observed in 47 (42.3%) of 111 patients in the 
placebo group and 31 (30.1%) of 103 patients in the Lactobacil-
lus group (P=0.08) (Table 3). The results of multivariate analysis 
of the OR of Lactobacillus for AAD-1, AAD-2, and change in bow-
el frequency and consistency are shown in Table 4. The Lacto-
bacillus group was less likely to experience changes in bowel fre-
quency and consistency compared with the placebo group (OR 
0.43, 95% CI 0.25-0.82), which means that although Lacidofil® 
cap does not reduce the rate of occurrence rate of AAD in adult 
patients with respiratory tract infection who have taken antibi-
otics, the Lactobacillus group maintained their bowel habits to 
a greater extent than the placebo group.
 In PP analysis (n=172, excluding 42 patients who dropped 
out), AAD-1 developed in 3 (3.6%) of 83 patients in the Lactoba-
cillus group and in 5 (5.6%) of 89 patients in the placebo group 
(P=0.72). AAD-2 developed in 8 (9.6%) of 103 patients in the 
Lactobacillus group and in 9 (10.1%) of 89 patients in the place-
bo group (P=1.00). However, normal bowel movement was re-
ported by 36 (43.4%) of 83 patients in the Lactobacillus group and 
27 (30.3%) of 89 patients in the placebo group (P=0.10) (Table 
5). The results of multivariate analysis of the OR of Lactobacillus 
for AAD-1, AAD-2, and change in bowel frequency and consis-
tency are shown in Table 6. The OR for no change in bowel fre-
quency and consistency was 0.53 (95% CI 0.27-1.05, P=0.07).
Risk factors for AAD
The results of ITT analysis (n=214) of risk factors for AAD-1 (n= 
12) and non-AAD-1 (n=202) are shown in Table 7. AAD-1 was 
Table 2. Antibiotics use in the placebo and the Lactobacillus groups
Antibiotics in use
Placebo  
(n=111)
Lactobacillus 
(n=103)
P value
Cephalosporins   83 (74.8%) 80 (77.7%) 0.73
Macrolides   47 (42.3%) 47 (45.6%) 0.72
Fluoroquinolones   38 (34.2%) 40 (38.8%) 0.57
Antituberculosis drugs   18 (16.2%) 11 (10.7%) 0.32
Clindamycin 10 (9.0%) 8 (7.8%) 0.93
Penicillin   6 (5.4%) 5 (4.9%) 1.00
Aminoglycosides   6 (5.4%) 4 (3.9%) 0.74
Metronidazole   4 (3.6%) 3 (2.9%) 1.00
Sulfamethoxazole/trimethoprim   1 (0.9%) 3 (2.9%) 0.35
Glycopeptides   1 (0.9%) 0 (0.0%) 1.00
β-lactam antibiotics*   84 (75.7%) 81 (78.6%) 0.72
*Cephalosporins plus penicillin.
Table 3. Comparison of AAD between the placebo and the Lactobacillus groups (ITT 
analysis, n=214)
Outcomes
Placebo 
(n=111)
Lactobacillus 
(n=103)
P value
AAD-1 (primary outcome), n=12 8 (7.2%) 4 (3.9%) 0.44
AAD-2 (secondary outcome), n=25 16 (14.4%) 9 (8.7%) 0.28
No change in bowel frequency   
   and consistency
35 (31.5%) 50 (48.5%) 0.01
Increased bowel frequency more than 
   3 days during the 14-day period
47 (42.3%) 31 (30.1%) 0.08
Table 4. Odds ratio of Lactobacillus ( ITT analysis, n=214)
Outcomes
Odds ratio* (CI)  
of Lactobacillus 
P value
AAD-1 (primary outcome), n=12 0.53 (0.13-2.07) 0.36
AAD-2 (secondary outcome), n=25 0.57 (0.22-1.45) 0.23
No change in bowel frequency and consistency 0.45 (0.25-0.82) 0.01
Increased bowel frequency more than 3 days  
   during the 14 day period
0.62 (0.34-1.12) 0.11
*Logistic analysis: adjusted for age, baseline bowel movement, medical illness, duration 
of total antibiotic use, and remnant drugs. 
CI, confidence interval.
Table 5. Comparison of AAD between the placebo and the Lactobacillus groups (PP 
analysis, n=172)
Outcomes
Placebo  
(n=89)
Lactobacillus 
(n=83)
P value
AAD-1 (primary outcome), n=8 5 (5.6%) 3 (3.6%) 0.72
AAD-2 (secondary outcome), n=17   9 (10.1%) 8 (9.6%) 1.00
No change in bowel frequency   
   and consistency
27 (30.3%) 36 (43.4%) 0.10
Increased bowel frequency more  
   than 3 days during the 14-day period
38 (42.7%) 28 (33.7%) 0.29
Table 6. Odds ratio of Lactobacillus (PP analysis, n=172)
Outcomes
Odds ratio* (CI) of 
Lactobacillus 
P value
AAD-1 (primary outcome), n=12 0.64 (0.14-2.92) 0.56
AAD-2 (secondary outcome), n=25 1.02 (0.35-2.96) 0.96
No change in bowel frequency  
   and consistency
0.53 (0.27-1.05) 0.07
Increased bowel frequency more than 3 days  
   during the 14 day period
0.75 (0.39-1.45) 0.39
*Logistic analysis: adjusted for age, baseline bowel movement, medical illness, and 
duration of total antibiotic use. 
CI, confidence interval.
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more prevalent in patients with no medical illness (75.0% vs 
40.6%) (P=0.04) and those with a longer duration of antibiotic 
use (13.8±2.0 vs 11.9±3.6 days) (P=0.01). There was also a ten-
dency for AAD-1 patients to have greater baseline bowel move-
ment (1.4±0.7 vs 1.0±0.4 per day) (P=0.08), remnant drugs (9.2± 
11.4 vs 3.6±7.5 capsules) (P=0.06) or to use β-lactam antibiotics 
(100% vs 75.7%) (P=0.07). AAD-2 was more prevalent in patients 
who were younger (53±16 vs 62 ±15 yr) (P=0.01), had no medical 
illness (68.0% vs 39.2%) (P=0.01) or had a longer duration of 
antibiotic use (13.5±1.8 vs 11.8±3.7 days) (P=0.01). In addition, 
patients who developed AAD-2 had a tendency to have greater 
baseline bowel movement (1.3±0.6 vs 1.0±0.4 per day) (P=0.05), 
remnant drugs (5.8±8.8 vs 3.7±7.7 capsules) (P=0.07), or to use 
β-lactam antibiotics (92.0% vs 75.1%) (P=0.10).
 The results of PP analysis (n=172) of the risk factors for AAD-
1 (n=8) and non-AAD-1 (n=164) are shown in Table 8. AAD-1 
tended to occur in patients who were younger (50±19 vs 60±16 
yr) (P=0.06), or had elevated baseline bowel movement (1.4±0.5 
vs 1.0±0.4 per day) (P=0.05). AAD-2 was more prevalent in pa-
tients who were young (51±16 vs 61±16 yr) (P=0.01), had a med-
ical illness (23.5% vs 58.7%) (P=0.01), had a longer duration of 
antibiotic use (13.6±1.9 vs 12.3±3.4 days) (P=0.02) or use β-lactam 
antibiotics (100% vs 78.1%) (P=0.02). In addition, patients with 
AAD-2 had a tendency to have an increased baseline bowel 
movement (1.3±0.5 vs 1.0±0.4 per day) (P=0.06).
Adverse events
Mild abdominal discomfort was reported by 1 patient (0.9%) in 
the placebo group and by 3 patients (2.9%) in the Lactobacillus 
group (P=0.35). Skin eruption was reported by 1 patient (0.97%) 
in the Lactobacillus group. However, there were no significant 
adverse events associated with the use of Lacidofil® cap.
DISCUSSION
This study evaluated the efficacy of a Lactobacillus probiotic 
single-agent regimen for AAD. In our study, the number of AAD 
cases was not statistically different between the 2 groups and 
the prevalence of AAD was low (3.9-7.2%) compared with a pre-
vious report (2-25%) as assessed by ITT analysis (2). This result 
may be attributed to the short-term follow-up period because 
AAD may occur up to 2 months after stopping antibiotic treat-
ment (1). Recent meta-analysis of 10 randomized, blinded, pla-
cebo-controlled trials showed that the combined risk ratio (RR) 
Table 7. Risk factors for AAD ( ITT analysis, n=214)
Factors
AAD-1  
(n=12)
Non-AAD-1  
(n=202)
P value
AAD-2  
(n=25)
Non-AAD-2  
(n=189)
P value
Sex (male:female) 10:2 122:80 0.13 17:8 115:74 0.63
Age (yr)   54±17   61±15 0.15   53±16   62±15 0.01
BMI (kg/m2) 22.8±3.3 22.2±3.3 0.51 21.8±3.1 22.2±3.4 0.62
No medical illness      9 (75.0%)   82 (40.6%) 0.04   17 (68.0%)   74 (39.2%) 0.01
Baseline bowel movement (per day)   1.4±0.7   1.0±0.4 0.08   1.3±0.6   1.0±0.4 0.05
Loose stool or watery diarrhea in normal condition 0 (0%)   3 (1.0%) 1.00 0 (0%)   3 (1.6%) 1.00
Total antibiotic use (days) 13.8±2.0 11.9±3.6 0.01 13.5±1.8 11.8±3.7 0.01
No. of combined antibiotics   3.2±1.2   2.7±0.7 0.25   3.0±1.1   2.7±1.3 0.23
Remnant drugs (capsules)     9.2±11.4   3.6±7.5 0.06   5.8±8.8  3.7 ±7.7 0.07
Pneumonia    10 (83.3%) 140 (73.8%) 0.73   20 (80.0%) 139 (73.5%) 0.65
Tuberculosis      3 (25.0%)   25 (12.4%) 0.19     4 (16.0%)   24 (12.7%) 0.75
β-lactam antibiotics      12 (100.0%) 153 (75.7%) 0.07   23 (92.0%) 142 (75.1%) 0.10
Table 8. Risk factors for AAD (PP analysis, n=172)
Factors
AAD-1  
(n=8)
Non-AAD-1  
(n=164)
P value
AAD-2  
(n=17)
Non-AAD-2  
(n=155)
P value
Sex (male:female) 6:2 97:67 0.47 10:7 93:62 1.00
Age (yr)   50±19   60±16 0.06   51±16   61±16 0.01
BMI (kg/m2) 22.1±2.3 22.3±3.4 0.84 21.8±2.6 22.4±3.5 0.49
No medical illness 6 (75.0%)   71 (43.3%) 0.14   4 (23.5%)   91 (58.7%) 0.01
Baseline bowel movement (per day)   1.4±0.5   1.1±0.4 0.05   1.3±0.5   1.0±0.4 0.06
Loose stool or watery diarrhea in normal condition 0 (0%)   3 (1.8%) 1.00 0 (0%)   3 (1.9%) 1.00
Total antibiotic use (days) 13.6±2.1 12.3±3.4 0.28 13.6±1.9 12.3±3.4 0.02
No. of combined antibiotics   3.3±1.2   2.8±1.3 0.30   3.0±1.1   2.8±1.3 0.47
Remnant drugs (capsules)   1.8±3.3   0.7±1.5 0.17   1.5±2.6   0.6±1.5 0.17
Pneumonia 6 (75.0%) 121 (73.8%) 1.00 13 (76.5%) 114 (73.6%) 1.00
Tuberculosis 3 (37.5%)   24 (14.6%) 0.11   4 (23.5%)   23 (14.9%) 0.31
β-lactam antibiotics   8 (100.0%) 130 (79.3%) 0.35   17 (100.0%) 121 (78.1%) 0.02
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of developing AAD was significantly lower in the Lactobacillus 
groups than in the placebo group (RR 0.35, 95% CI 0.19-0.67) 
(19). Large differences exist among trials, including our study. 
The indications for antibiotic therapy differed among the stud-
ies and included respiratory tract infection, otitis media, urinary 
tract infection and Helicobacter pylori infection (19).
 According to a previous report, doses used in Lactobacillus 
regimens range from 2×109 to 4×1010 colony-forming units per 
day (19). There was considerable variation in the probiotic regi-
mens used. It has been suggested that doses of probiotics should 
exceed 1010 colony-forming units per day (10). In our study, the 
dose of the Lactobacillus regimen was 4×109 colony-forming 
units. This may be the reason why the Lactobacillus group prep-
aration did not exhibit a protective effect for AAD. Thus, it is ex-
pected that if the does had been greater (>1010 colony-forming 
units per day), it may have had a preventive effect on AAD. The 
effects of increasing dosages of probiotics should be monitored, 
irrespective of whether adverse events are expected. Further 
evaluations using standardized Lactobacillus dosage forms and 
regimens are warranted.
 AAD was defined as loose or watery stools more than 3 times 
per day for at least 2 days. This stringent definition enabled us 
to differentiate between clinically relevant and clinically unim-
portant changes in the consistency of stools. The secondary out-
come, AAD-2, was defined as loose or watery stools more than 
2 times per day for at least 2 days. However, definitions of AAD 
vary between published studies. For example, Vanderhoof et al. 
defined diarrhea as ≥2 liquid stools per 24 hr on ≥2 days (13). 
Bowel frequency and consistency reflects bowel habits. Tables 
3 and 4 showed that there were significant differences in bowel 
frequency and consistency. These results suggest that mainte-
nance of usual bowel habit was promoted by the probiotic. This 
result is consistent with that of a previous trial (20) performed 
on children. Although the overall incidence of diarrhea was sur-
prisingly low and the administration of a combination of Bifi-
dobacterium longum PL03, L. rhamnosus KL53A, and L. plan-
tarum PL02 did not significantly alter the incidence of diarrhea, 
it reduced the daily frequency of stools (20).   
 In our study, ITT (n=214) analysis gave better results than PP 
(n=172) analysis. Forty-two patients did not complete the study. 
Thus, the number of patients enrolled was less than that required 
to achieve the target statistical power for the PP analysis. Stud-
ies involving larger numbers of patients are necessary. Regard-
ing risk factors, patients who had elevated baseline bowel move-
ments, more remnant drugs, and greater use of β-lactam antibi-
otics had higher incidences of AAD-1 and AAD-2. These results 
show that patients with elevated bowel movement and low drug 
compliance had a higher incidence of AAD. However, increased 
bowel movements may have affected the underlying risk for de-
velopment of AAD or their response to the probiotic. Thus, for 
analysis of the OR of Lactobacillus (Tables 4, 6), we adjusted the 
data for baseline bowel movement and other confounding fac-
tors (age, medical illness, duration of total antibiotic use, and 
remnant drugs). β-lactam antibiotics, including penicillin and 
cephalosporins, are proven risk factors for AAD (1). In addition, 
AAD was more prevalent in subjects who were young, had no 
medical illness and had used antibiotics for a long period. Our 
result is not in accord with that of a previous report (1). The rea-
son for this may be selection bias in our study.
 L. rhamnosus has inhibitory activity against a wide range of 
bacteria, including C. difficile (21). In addition, L. rhamnosus is 
expected to be useful for the prevention of AAD because it sur-
vives the digestive process and is not killed by the acidic pH of 
the stomach or by bile (22). When administered exogenously, L. 
rhamnosus persists in the colon for at least a week and modifies 
the colonic environment with potential positive health effects 
(23, 24). There are 3 reports showing L. rhamnosus prevents AAD 
in children (12-14). For adults, 2 reports have been published 
concerning the synergistic effect of L. rhamnosus with anti-H. 
pylori eradication therapy (11, 16). The rationale for the use of 
probiotics is that the use of antibiotics may result in a disturbance 
of the normal intestinal microflora, which is one of the key fac-
tors in the pathogenesis of AAD and C. difficile infection (25). 
There are several possible mechanisms by which probiotics, in-
cluding Lactobacillus, exert preventative effects on AAD. These 
include the synthesis of antimicrobial substances (17, 22, 26), 
competition for nutrients required for the growth of pathogens, 
competitive inhibition of adhesion of pathogens, and modifica-
tion of toxins or toxin receptors (27).
 Concerns about the safety of probiotics have been raised be-
cause probiotics are living organisms that, when given to ill pa-
tients, could elicit adverse reactions. As some intestinal bacteria 
have been shown to migrate from the intestine to other organs, 
antibiotic-resistant gene acquisition is also a potential concern 
(10). Although bacteremia and fungemia have been reported in 
the literatures (28, 29), our study showed only mild abdominal 
discomfort in 1 patient and skin eruption in 3 patients without 
any significant adverse events. Caution should be exercised for 
patients who are severely ill and are receiving nutrition or anti-
biotics through a potentially open portal catheter or a nasogas-
tric tube.  
 Our study had some limitations. First, the incidence of AAD 
was much lower in our study than in previous studies. Our pa-
tients were followed up for only 2 weeks after antibiotic therapy. 
As AAD can occur up to 2 months after stopping antibiotic treat-
ment (1), some cases might have been missed. Second, the pa-
tients were not normally distributed. Some centers recruited 
more patients than allocated, and others had fewer cases. This 
imbalance was caused by differences in the hospital size and 
location, and the incidence of antibiotic-naïve respiratory infec-
tions at the hospitals. Third, the difference between hospitals in 
the main antibiotic prescribed is a potential weakness because 
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the incidence of AAD differs between groups of antibiotics. How-
ever, there was no significant difference in antibiotic use between 
the 2 groups. Finally, although the required sample size was 220, 
we performed the study using 214 patients. The most frequent 
limitation of previous studies may also have been insufficient 
power to detect significant differences (19). Few investigators 
have calculated required sample sizes, and 3 investigators re-
ported that slow recruitment of study patients resulted in pre-
mature termination of the trial (10, 30). However, our study has 
value as the first prospective, randomized, double-blind, multi-
center study on the effect of probiotic Lactobacillus for the pre-
vention of AAD in Korea.
 In conclusion, although Lacidofil® cap does not reduce the 
occurrence of AAD in adult patients with respiratory tract infec-
tion who have taken antibiotics, the Lactobacillus group main-
tains their bowel habits to a greater extent than the placebo group 
without any significant adverse events.
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